Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the JMP Securities Healthcare Conference on Wednesday, July 10, 2013 at 3:00 p.m. ET in New York, New York.
The event will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website at www.anacor.com. A replay will also be available for three months following the presentation.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing
and commercializing novel small-molecule therapeutics derived from its
boron chemistry platform. Anacor has discovered eight compounds that are
currently in development. Its two lead product candidates are topically
administered dermatologic compounds — tavaborole, a topical antifungal
for the treatment of onychomycosis, and AN2728, a topical
anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis
and psoriasis. In addition to its two lead programs, Anacor has
discovered three other wholly-owned clinical product candidates — AN2718
and AN2898, which are backup compounds to tavaborole and AN2728,
respectively, and AN3365 (formerly known as GSK2251052, or GSK ‘052), an
antibiotic for the treatment of infections caused by Gram-negative
bacteria, which previously was licensed to GlaxoSmithKline LLC, or GSK.
GSK has returned all rights to the compound to us and we are considering
our options for further development, if any, of this compound. We have
discovered three other compounds that we have out-licensed for further
development — two compounds for the treatment of animal health
indications that are licensed to Eli Lilly and Company and AN5568, also
referred to as SCYX-7158, for human African trypanosomiasis (HAT, or
sleeping sickness), which is licensed to Drugs for Neglected Diseases
initiative, or DNDi. We also have a pipeline of other internally
discovered topical and systemic boron-based compounds in development.
For more information, visit
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV